RDRobert DiCenzo

Robert DiCenzo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert DiCenzo has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Giovanni Schifitto

    University at Buffalo, Buffalo, New York,1 University of Rochester, Rochester, New York,2 University of North Carolina, Chapel Hill, North Carolina3

    2 shared publications
  • Harris A. Gelbard

    University of Rochester Medical Center

    2 shared publications
  • Kim Cruttenden

    University at Buffalo, Buffalo, New York,1 University of Rochester, Rochester, New York,2 University of North Carolina, Chapel Hill, North Carolina3

    2 shared publications
  • Richard Reichman

    Department of Medicine, Infectious Diseases Unit, University of Rochester, Rochester, New York

    2 shared publications
  • Alan Forrest

    University of Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York

    1 shared publication
  • Amneris Luque

    Infectious Disease Unit, Department of Medicine, University of Rochester Rochester, NY, USA

    1 shared publication

Latest Publications

  • Effects of Minocycline and Valproic Acid Coadministration on Atazanavir Plasma Concentrations in Human Immunodeficiency Virus-Infected Adults Receiving Atazanavir-Ritonavir

    by Robert DiCenzo, Derick R. Peterson, Kim Cruttenden, Peter Mariuz, Naser L. Rezk, Jill Hochreiter, Harris Gelbard, Giovanni Schifitto

    Minocycline and valproic acid are potential adjuvant therapies for the treatment of human immunodeficiency virus (HIV)-associated cognitive impairment. The purpose of this study was to determine whether minocycline alone or in combination with valproic acid affected atazanavir plasma concentrations. Twelve adult HIV-infected subjects whose regimen included atazanavir (300 mg)-ritonavir (100 mg) daily for at least 4 weeks were enrolled. Each subject received atazanavir-ritonavir on day 1, atazanavir-ritonavir plus 100 mg minocycline twice daily on days 2 to 15, and atazanavir-ritonavir plus 100 mg minocycline twice daily and 250 mg valproic acid twice daily on days 16 to 30 with meals. The subjects had 11 plasma samples drawn over a dosing interval on days 1, 15, and 30. The coadministration of minocycline and valproic acid with atazanavir-ritonavir was well tolerated in all 12 subjects (six male; mean [± standard deviation] age was 43.1 [8.2] years). The geometric mean ratios (GMRs; 95% confidence interval [CI]) for the atazanavir area under the concentration-time curve from 0 to 24 h at steady state (AUC 0-24 ), the plasma concentration 24 h after the dose ( C min ), and the maximum concentration during the dosing interval ( C max ) with and without minocycline were 0.67 (0.50 to 0.90), 0.50 (0.28 to 0.89), and 0.75 (0.58 to 0.95), respectively. Similar decreases in atazanavir exposure were seen after the addition of valproic acid. The GMRs (95% CI) for atazanavir AUC 0-24 , C min , and C max with and without minocycline plus valproic acid were 0.68 (0.43 to 1.06), 0.50 (0.24 to 1.06), and 0.66 (0.41 to 1.06), respectively. Coadministration of neither minocycline nor minocycline plus valproic acid appeared to influence the plasma concentrations of ritonavir ( P > 0.2). Minocycline coadministration resulted in decreased atazanavir exposure, and there was no evidence that the addition of valproic acid mediated this effect.


  • Effect of Quercetin on the Plasma and Intracellular Concentrations of Saquinavir in Healthy Adults

    by Robert DiCenzo, Valerie Frerichs, Panupong Larppanichpoonphol, Lisa Predko, Amy Chen, Richard Reichman, Marilyn Morris

    Study Objectives. To determine if quercetin, a bioflavonoid that inhibits p‐glycoprotein, alters plasma saquinavir concentrations, and to explore the potential influence on intracellular concentrations.Design. Prospective pharmacokinetic analysis.Setting. University‐affiliated general clinical research center.Subjects. Ten healthy adults (four women, six men) with a mean ± SD age of 30.7 ± 9.4 years.Intervention. All subjects received saquinavir 1200 mg 3 times/day with food on days 1–11 and quercetin 500 mg 3 times/day with food on days 4–11.Measurements and Main Results. On days 4 and 11, nine blood samples and four peripheral blood mononuclear cell samples were drawn during a steady‐state dosing interval. Pharmacokinetic parameters were calculated by using standard noncompartmental techniques. Plasma saquinavir concentrations were similar regardless of quercetin administration. Geometric mean ratios for the area under the concentration‐time curve during an 8‐hour dosing interval (AUC0–8), maximum concentration in the dosing interval, and minimum concentration in the dosing interval were 0.99 (95% confidence interval [CI] 0.65–1.50), 0.99 (95% CI 0.64–1.54), and 1.06 (95% CI 0.68–1.67), respectively. Intracellular saquinavir concentrations displayed substantial intra‐ and intersubject variability, which limited the ability to determine the influence of quercetin coadministration (geometric mean ratio for AUC0–8 = 0.51 [95% CI 0.14–1.95], six patients).Conclusion. Quercetin coadministration did not influence plasma saquinavir concentrations. Because of substantial inter‐ and intrasubject variability, more study is necessary to determine if saquinavir intracellular concentrations are altered by coadministration of quercetin.


  • Open Access

    Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens

    by Robert Dicenzo, Amneris Luque, Panupoong Larppanichpoonphol, Richard Reichman

    Objectives: The purpose of this study was to determine the pharmacokinetics and tolerability of three different indinavir and lopinavir/ritonavir dosing regimens. Methods: HIV-infected adults receiving lopinavir/ritonavir 400/100 mg twice daily with food had nine plasma samples taken over a 12 h dosing interval at baseline (BL), after adding indinavir 600 mg twice daily for 10 days (R1), indinavir 800 mg twice daily for 5 days (R2) and lopinavir/ritonavir 533/133 mg plus indinavir 600 mg twice daily for 10 days (R3). Plasma samples were assayed using HPLC. Results: A total of 12 patients completed the BL visit [10 male; mean (SD) age = 43.9 (5.8) years] and 9, 7 and 7 completed R1, R2 and R3 visits, respectively. Two subjects discontinued treatment due to hypertriglyceridaemia. Compared with BL, the R3 lopinavir AUC (P < 0.05) and Cmin (P = 0.0025) were significantly higher and the R2 AUC trended higher (P = 0.09). The indinavir AUC (P = 0.030) and Cmax (P = 0.035) were significantly higher for R2 compared with R1. There was a trend for increased total bilirubin (TB) after the addition of indinavir (P=0.09). Lopinavir and indinavir AUC, Cmax and Cmin were associated with TB during univariate analyses (P < 0.01) while only lopinavir AUC (P = 0.0004) and indinavir AUC (P = 0.0028) were associated with TB during multivariate analysis. Only indinavir AUC was significant when both drugs were included in the model (P = 0.0028). Conclusions: Elevated lopinavir and indinavir concentrations are associated with elevated TB.


  • Effects of Valproic Acid Coadministration on Plasma Efavirenz and Lopinavir Concentrations in Human Immunodeficiency Virus-Infected Adults

    by Robert DiCenzo, Derick Peterson, Kim Cruttenden, Gene Morse, Garret Riggs, Harris Gelbard, Giovanni Schifitto

    Valproic acid (VPA) has the potential to benefit patients suffering from human immunodeficiency virus (HIV)-associated cognitive impairment. The purpose of this study was to determine if VPA affects the plasma concentration of efavirenz (EFV) or lopinavir. HIV type 1 (HIV-1)-infected patients receiving EFV or lopinavir-ritonavir (LPV/r) had 9 or 10 blood samples drawn over 8 to 24 h of a dosing interval at steady state before and after receiving 250 mg of VPA twice daily for 7 days. VPA blood samples drawn before (C0) and 8 h after the morning dose (8 h) were compared to blood samples from a group of HIV-1-infected subjects who were taking either combined nucleoside reverse transcriptase inhibitors alone or had discontinued antiretroviral therapy. Pharmacokinetic parameters were calculated by noncompartmental analysis, and tests of bioequivalence were based on 90% confidence intervals (CIs) for ratios or differences. The geometric mean ratio (GMR) (90% CI) of the areas under the concentration-time curve from 0 to 24 h (AUC0-24s) of EFV (n= 11) with and without VPA was 1.00 (0.85, 1.17). The GMR (90% CI) of the AUC0-8s of LPV (n= 8) with and without VPA was 1.38 (0.98, 1.94). The differences (90% CI) in meanC0and 8-h VPA concentrations versus the control (n= 11) were −1.0 (−9.4, 7.4) μg/ml and −2.1 (−11.1, 6.9) μg/ml for EFV (n= 10) and −5.0 (−13.2, 3.3) μg/ml and −6.7 (−17.6, 4.2) μg/ml for LPV/r (n= 11), respectively. EFV administration alone is bioequivalent to EFV and VPA coadministration. LPV concentrations tended to be higher when the drug was combined with VPA. Results of VPA comparisons fail to raise concern that coadministration with EFV or LPV/r will significantly influence trough concentrations of VPA.


  • A Gentamicin Pharmacokinetic Population Model and Once‐Daily Dosing Algorithm for Neonates

    by Robert DiCenzo, Alan Forrest, Judianne C. Slish, Carol Cole, Ronnie Guillet

    Study Objective . To develop a gentamicin pharmacokinetic population model and once‐daily dosing algorithm for neonates younger than 10 days. Design . Prospective, open‐label study. Setting . Neonatal intensive care unit. Patients . One hundred thirty‐nine neonates prescribed gentamicin. Measurements and Main Results . Gentamicin peak and trough serum concentrations were collected from 139 neonates divided into three groups who were receiving one of the following intravenous 24‐hour gentamicin regimens during the first 10 days of life, based on gestational age and birth weight (group 1, < 28 wks, 2.5 mg/kg; group 2, 28–34 wks, 3 mg/kg; and group 3, > 34 wks, 4 mg/kg). A structural model was developed in ADAPT II software using a MAP Bayesian approach. Final population parameter estimates were calculated using iterative two‐stage analysis. The median (range) gestational age and birth weight, respectively, were 32 weeks (23–42 wks) and 1.92 kg (0.47–5.00 kg). The final one‐compartmental linear model had a median (range) gentamicin total clearance, half‐life, and volume of distribution of 0.0709 L/hour (0.0151–0.246 L/hr), 8.59 hours (4.88–16.9 hrs), and 0.262 L (0.0903–0.929 L), respectively. Total clearance increased as gestational age increased (p2 ] = 0.897), and volume of distribution was associated with birth weight (r 2 = 0.700). The following dosing algorithm was designed to reach a therapeutic 24hour area under the curve (87.5 mg/L·hr) in neonates during the first 10 days after birth: 24‐hour gentamicin dose (mg) = (0.441 + [0.0945 · gestational age]) · birth weight. Conclusion . This dosing algorithm provides a new approach for determining initial gentamicin dosing regimens in neonates; however, clinical validation is required.